NASDAQ: SHC · Diagnostics & Research
Sotera Health (SHC) fair value: undervalued or overvalued?
As of 7 Nov 2026, Faircurve's model values Sotera Health (SHC) at $21.71 a share. The stock last closed at $16.01, which puts the model's fair value 35.6% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 6 Nov 2026. Sotera Health Company.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 7 Nov 2026 moved the fair value from $27.14 to $21.71 (-20.0%). The multiple the model anchors on moved, lowering the fair value: most of the move.
What the model makes of itThe price of $16.01 is 35.6% below it: Undervalued, on a high evidence grade.
What's nextNext report on 23 Feb 2027. The next weekly run is on Saturday 14 Nov 2026.
What price range does the model give SHC?
The calibrated range for SHC over 63 trading days is $17.45 to $25.86. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 11,845 past valuations, refreshed 7 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The price is below this range. For names with fair value 30%+ above price, the calibrated range has held the price 23% of the time over 63 trading days, and 77% ended below it; the typical move was +0.3%.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $17.36 to $26.47. In 88% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 7 Nov 2026
Sotera Health Company is headquartered in Broadview Heights, Ohio. It delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions.
Faircurve's model puts the fair value of Sotera Health Company (SHC) at $21.71 a share, the midpoint of 2,000 simulations, on the run of 7 Nov 2026. The previous run, on 31 Oct 2026, gave $27.14, so the fair value moved -20.0%. The model says the multiple it anchors on moved, lowering the fair value: most of the move. The calibrated range over 63 trading days is $17.45 to $25.86. It is built from the fair value, as there is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High, based on input completeness, the number of comparable companies and how closely they agree, and the spread of outcomes. It does not say whether the fair value is right.
The model's overall quality score for Sotera Health is 57 out of 100, against comparable companies. Profitability scores 100, with ROIC at 11.1% against a peer median of 2.4%. Capital discipline scores 7, with net buybacks at 0.0% of market value against a peer median of 0.8%. Stability scores 29, with five-year EBITDA margin downside volatility at 14.9 pts against a peer median of 5.6 pts. The comparable companies are RadNet, NeoGenomics, Charles River Laboratories, Revvity, Medpace, Quest Diagnostics and Labcorp.
Written from the figures on this page for the 7 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does SHC report earnings, and how has the stock reacted?
Sotera Health's next earnings report is scheduled for 23 Feb 2027. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across SHC's last 8 reports, ignoring direction, was 6.2%.
How does SHC score on business quality?
Sotera Health's overall quality score is 57 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 100 | 11.1%ROIC | 2.4% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 47 | 0.78xFCF / net income | 1.58x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 55 | 5.7%Revenue growth, trailing | 2.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 7 | 0.0%Net buybacks / market value | 0.8% |
| Balance sheetNet debt to EBITDA and interest coverage. | 33 | 3.44xNet debt / EBITDA | 2.21x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 29 | 14.9 ptsEBITDA margin downside volatility, 5y | 5.6 pts |
How does SHC compare with similar companies?
The companies in diagnostics & research closest to Sotera Health in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| RDNT RadNet, Inc. | $76.00 | $78.41 | +3.2% | Fairly valued |
| NEO NeoGenomics, Inc. | $16.84 | $16.48 | -2.1% | Fairly valued |
| VCYT Veracyte, Inc. | $24.16 | $27.66 | +14.5% | Data under review |
| CRL Charles River Laboratories International, Inc. | $337.52 | $429.83 | +27.3% | Undervalued |
| RVTY Revvity, Inc. | $155.11 | $188.92 | +21.8% | Undervalued |
| MEDP Medpace Holdings, Inc. | $653.11 | $721.49 | +10.5% | Fairly valued |
| DGX Quest Diagnostics Incorporated | $255.63 | $302.79 | +18.4% | Undervalued |
| LH Labcorp Holdings Inc. | $366.57 | $435.58 | +18.8% | Undervalued |
What the comparable companies' multiples alone would give for SHC, the peer-implied price, is $46.23 a share on this run. The fair value weighs that against the company's own multiple.
All diagnostics & research stocks ranked by gap to fair value
Sotera Health at a glance
Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions.
- Market value
- $4.6B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Revenue expected, next twelve months
- $1.3B
- Consensus revenue growth, next fiscal year
- +7.0%
- Analysts with estimates
- 5
- Beta to the US market
- 0.85
- First valued by Faircurve
- 11 Jul 2026
At the close of 6 Nov 2026, 53.0% of the 1,067 graded US stocks the model covers traded below the model's fair value. SHC was among them.
How the fair value is worked out: the model prices Sotera Health on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 31 Oct 2026 the model's fair value for SHC was $27.14. As of 7 Nov 2026 it is $21.71, a change of -20.0%. The multiple the model anchors on moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Sotera Health's valuation
Is Sotera Health stock undervalued or overvalued?
On Faircurve's model, SHC reads as Undervalued as of 7 Nov 2026. The model's fair value is $21.71 a share against a last close of $16.01, a gap of +35.6%.
What is SHC's fair value?
$21.71 a share as of 7 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $17.36 to $26.47.
What price range does the model give SHC?
$17.45 to $25.86 over 63 trading days. Ranges built this way held the price 60% of the time across 11,845 past valuations, refreshed 7 Nov 2026.
When does Sotera Health report earnings next?
The next report is scheduled for 23 Feb 2027. Companies can move their dates.
How much has SHC moved on past earnings reports?
Across its last 8 reports the median two session move was 6.2%, ignoring direction. The largest was +25.3% around the report of 8 Aug 2025.
How confident is the model in this valuation?
The model's evidence grade for SHC is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on SHC
The model holds no idea open on SHC today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on SHC with their outcomes. A free account is enough.